Thomson Medical Group (A50) Fair Value & Analysis
Healthcare · SG · Market cap 1.4B SGD
Fair value as of: Jul 4, 2026
From 13 valuation models · updated today
Share price −5.4% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0430 SGD – 0.0640 SGD · fair‑value band 0.0302 SGD – 0.0461 SGD · the 0.0530 SGD price screens above the 0.0302 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Thomson Medical Group (A50) currently trades at 0.0530 SGD, while our model-based Fair Value estimate is 0.0302 SGD — implying the stock looks roughly 43.0% overvalued today. We read business quality at 50/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Thomson Medical Group generated revenue of 470M SGD at a net margin of -9.6%. Revenue grew 6.9% year over year. It earns a return on equity of -7.5%. Net debt stands at 982M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Thomson Medical Group Limited, an investment holding company, provides healthcare services for women and children in Singapore, Malaysia, and Vietnam. The company owns and operates the Thomson Medical Centre, as well as a network of medical clinics and facilities. It also offers urgent care services, such as basic resuscitation, ECG, vaccinations, IM/IV fluid and IV antibiotic administration, surgeries and procedures, wound care and stitching, and X-ray and basic laboratory tests; health screening services; services related to skin and aesthetics, and pain and rehab management; and herbal tea. In addition, the company provides specialized services, such as women's health, children's health, fertility and family planning, eye health, general surgery, urology, preventive health and healthy ageing, diagnostic imaging, breast health, cardiology, respiratory medicine and critical care, endocrinology, dermatology, day surgery, surgical care, counselling and therapy, traditional Chinese …
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Thomson Medical Group reported revenue of 395M SGD in FY2024 versus 240M SGD in FY2020, a compound +13.2%/yr. Reported net income was −47.6M SGD in FY2024.
Is A50 fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Thomson Medical Group (A50) undervalued?
What is the fair value of A50?
What is the quality score of A50?
What is the revenue of Thomson Medical Group (A50)?
What is the net profit margin of A50?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.